Compare BWB & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BWB | TECX |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | 337 | 60 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.7M | 549.5M |
| IPO Year | N/A | N/A |
| Metric | BWB | TECX |
|---|---|---|
| Price | $21.10 | $34.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $21.67 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 247.7K | 125.8K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.57 | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.90 | $14.39 |
| 52 Week High | $21.23 | $35.99 |
| Indicator | BWB | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 71.19 |
| Support Level | $16.33 | $27.31 |
| Resistance Level | N/A | $35.99 |
| Average True Range (ATR) | 0.49 | 1.77 |
| MACD | 0.12 | 0.42 |
| Stochastic Oscillator | 91.88 | 85.89 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.